| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.3390/IJMS20030719 |
| P953 | full work available at URL | https://www.mdpi.com/1422-0067/20/3/719 |
| P932 | PMC publication ID | 6386829 |
| P698 | PubMed publication ID | 30743990 |
| P50 | author | Michiel Van Bulck | Q64780314 |
| Jose A Morales-Garcia | Q42670619 | ||
| P2093 | author name string | Ana Perez-Castillo | |
| Ana Sierra-Magro | |||
| Michiel Van Bulck | |||
| Jesus Alarcon-Gil | |||
| Jose A. Morales-Garcia | |||
| P2860 | cites work | Neurodegeneration in Alzheimer's disease: caspases and synaptic element interdependence | Q21202836 |
| beta-Amyloid degradation and Alzheimer's disease | Q21284467 | ||
| Mechanism of action and in vivo role of platelet-derived growth factor | Q22010594 | ||
| USP30: a new promising target for Parkinson's disease? | Q86794892 | ||
| Increase in mortality rate in patients with dementia treated with atypical antipsychotics: a cohort study in outpatients in Central Italy | Q87364543 | ||
| A novel neuroregenerative approach using ET(B) receptor agonist, IRL-1620, to treat CNS disorders | Q89279339 | ||
| Mitochondrial dysfunction and neurodegenerative proteinopathies: mechanisms and prospects for therapeutic intervention | Q89480053 | ||
| Minocycline prevents the development of depression-like behavior and hippocampal inflammation in a rat model of Alzheimer's disease | Q90263636 | ||
| Nurr1 (NR4A2) regulates Alzheimer's disease-related pathogenesis and cognitive function in the 5XFAD mouse model | Q90267196 | ||
| TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease | Q91208089 | ||
| Altered neurogenesis in mouse models of Alzheimer disease. | Q52725068 | ||
| Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. | Q53222718 | ||
| Alzheimer's Disease: Past, Present, and Future. | Q53394172 | ||
| SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy. | Q54255866 | ||
| Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 | Q57058859 | ||
| Mitochondrial Targeting in Neurodegeneration: A Heme Perspective | Q57155833 | ||
| Mitochondrial therapeutic interventions in Alzheimer's disease | Q57190994 | ||
| Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons | Q57292355 | ||
| Vascular dementia | Q57813319 | ||
| Role of Presenilin in Mitochondrial Oxidative Stress and Neurodegeneration in | Q58704340 | ||
| Neuroprotection by immunomodulatory agents in animal models of Parkinson's disease | Q58775998 | ||
| Small Molecules as SIRT Modulators | Q59352551 | ||
| A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer's disease mouse model | Q59794685 | ||
| Synthesis and biological assessment of KojoTacrines as new agents for Alzheimer's disease therapy | Q59807620 | ||
| 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein | Q64863796 | ||
| Cardiovascular effects of centrally administered endothelin-1 and its relationship to changes in cerebral blood flow | Q70984685 | ||
| Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells | Q85668538 | ||
| CRMP-2 is involved in kinesin-1-dependent transport of the Sra-1/WAVE1 complex and axon formation | Q24293195 | ||
| The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy | Q24298748 | ||
| DJ-1 has a role in antioxidative stress to prevent cell death | Q24306633 | ||
| Parkin is recruited selectively to impaired mitochondria and promotes their autophagy | Q24317471 | ||
| Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice | Q24317631 | ||
| c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease | Q24318974 | ||
| Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease | Q24600153 | ||
| Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease | Q24673755 | ||
| Regulation of Neurogenesis by Neurotrophins during Adulthood: Expected and Unexpected Roles | Q26768228 | ||
| The Role of Oxidative Stress in Neurodegenerative Diseases | Q26771758 | ||
| Parkinson's disease, insulin resistance and novel agents of neuroprotection | Q26853311 | ||
| Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease | Q27025207 | ||
| APP Intracellular Domain Impairs Adult Neurogenesis in Transgenic Mice by Inducing Neuroinflammation | Q27322677 | ||
| Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease | Q27686808 | ||
| Alpha-synuclein in Lewy bodies | Q27860680 | ||
| Rescue of mesencephalic dopaminergic neurons in culture by low-level stimulation of voltage-gated sodium channels | Q28169166 | ||
| Sirtuin activators | Q28244893 | ||
| The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression | Q28250177 | ||
| Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death | Q28287762 | ||
| Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33 | Q28295382 | ||
| 'Rejuvenation' protects neurons in mouse models of Parkinson's disease | Q28305585 | ||
| A cell-penetrating ester of the neural metabolite lanthionine ketimine stimulates autophagy through the mTORC1 pathway: Evidence for a mechanism of action with pharmacological implications for neurodegenerative pathologies | Q28388679 | ||
| Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1 | Q28510145 | ||
| Genetic and chemical activation of TFEB mediates clearance of aggregated α-synuclein | Q28544679 | ||
| Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study | Q28546721 | ||
| Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease | Q28580559 | ||
| Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress | Q28592727 | ||
| Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. | Q28593258 | ||
| Mitochondrial dysfunction and oxidative damage in parkin-deficient mice | Q28593859 | ||
| Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's disease | Q28740634 | ||
| Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease | Q28742424 | ||
| Stimulation of endothelin B receptors by IRL-1620 decreases the progression of Alzheimer's disease | Q48155116 | ||
| Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease | Q48165108 | ||
| Effect of Metformin on Adult Hippocampal Neurogenesis: Comparison with Donepezil and Links to Cognition | Q48229855 | ||
| Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. | Q48348638 | ||
| Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein | Q48634030 | ||
| Effect of centrally administered endothelin agonists on systemic and regional blood circulation in the rat: role of sympathetic nervous system | Q48642003 | ||
| Protective effect of platelet-derived growth factor against 6-hydroxydopamine-induced lesion of rat dopaminergic neurons in culture | Q49121022 | ||
| Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats | Q49835581 | ||
| Current approaches to the treatment of Parkinson's Disease | Q50226283 | ||
| Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration | Q50479107 | ||
| Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity | Q50647423 | ||
| Acceleration of age-related learning and memory decline in middle-aged CD-1 mice due to maternal exposure to lipopolysaccharide during late pregnancy | Q50658381 | ||
| Endothelin receptor type B agonist, IRL-1620, prevents beta amyloid (Aβ) induced oxidative stress and cognitive impairment in normal and diabetic rats. | Q50686603 | ||
| Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system. | Q50884859 | ||
| Endothelin-converting enzyme-1 activity, endothelin-1 production, and free radical-dependent vasoconstriction in Alzheimer's disease. | Q51031098 | ||
| Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model. | Q52299253 | ||
| A Novel Therapeutic Approach to Treat Alzheimer's Disease by Neurotrophic Support During the Period of Synaptic Compensation. | Q52644594 | ||
| Mitochondria: the common upstream driver of amyloid-β and tau pathology in Alzheimer's disease. | Q37829753 | ||
| Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo | Q37869524 | ||
| Structure, function, and mechanism of progranulin; the brain and beyond | Q37892442 | ||
| Sirtuin activators and inhibitors | Q38021431 | ||
| Inflammation in neurodegenerative diseases--an update | Q38170472 | ||
| Role of zinc and copper ions in the pathogenetic mechanisms of Alzheimer's and Parkinson's diseases | Q38222379 | ||
| Apoptosis and oxidative stress in neurodegenerative diseases. | Q38233295 | ||
| Biometals and their therapeutic implications in Alzheimer's disease. | Q38263669 | ||
| Neural stem cells in Parkinson's disease: a role for neurogenesis defects in onset and progression | Q38268886 | ||
| Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. | Q38363823 | ||
| Adult neurogenesis in neurodegenerative diseases. | Q38400868 | ||
| A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit | Q38433785 | ||
| Mitochondria, autophagy and age-associated neurodegenerative diseases: New insights into a complex interplay | Q38445542 | ||
| Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinson's Disease. | Q38620227 | ||
| Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics | Q38627193 | ||
| Mechanisms of Neuronal Protection against Excitotoxicity, Endoplasmic Reticulum Stress, and Mitochondrial Dysfunction in Stroke and Neurodegenerative Diseases | Q38635692 | ||
| TREM2 in Neurodegenerative Diseases | Q38646212 | ||
| α-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading | Q38671037 | ||
| Biology of GDNF and its receptors - Relevance for disorders of the central nervous system | Q38717780 | ||
| Blood-brain barrier-supported neurogenesis in healthy and diseased brain. | Q38757773 | ||
| Therapeutic potential of autophagy-enhancing agents in Parkinson's disease. | Q38765856 | ||
| Simvastatin inhibits protein isoprenylation in the brain. | Q38770832 | ||
| Understanding Dopaminergic Cell Death Pathways in Parkinson Disease | Q38838505 | ||
| Drug treatments in Alzheimer's disease. | Q38850887 | ||
| Unconventional neurotrophic factors CDNF and MANF: Structure, physiological functions and therapeutic potential. | Q38899748 | ||
| CCAAT/enhancer binding protein β directly regulates the expression of the complement component 3 gene in neural cells: implications for the pro-inflammatory effects of this transcription factor. | Q38916940 | ||
| How neuroinflammation contributes to neurodegeneration | Q38931554 | ||
| Current and experimental treatments of Parkinson disease: A guide for neuroscientists | Q38941557 | ||
| Gene therapy targeting mitochondrial pathway in Parkinson's disease | Q38957332 | ||
| Shape matters: the complex relationship between aggregation and toxicity in protein-misfolding diseases | Q38981671 | ||
| The deubiquitinase USP15 antagonizes Parkin-mediated mitochondrial ubiquitination and mitophagy | Q38992751 | ||
| The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse. | Q39002911 | ||
| Human induced pluripotent stem cell-derived neurons improve motor asymmetry in a 6-hydroxydopamine-induced rat model of Parkinson's disease | Q39031960 | ||
| Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis | Q39057175 | ||
| A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease | Q39110459 | ||
| α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies | Q39124651 | ||
| Calcium signaling and molecular mechanisms underlying neurodegenerative diseases | Q39152527 | ||
| Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities | Q39171378 | ||
| Endothelin-1 is elevated in Alzheimer's disease and upregulated by amyloid-β. | Q39397123 | ||
| Alzheimer's disease: as it was in the beginning | Q39432741 | ||
| Dose-dependent and sequence-sensitive effects of amyloid-beta peptide on neurosteroidogenesis in human neuroblastoma cells | Q40009529 | ||
| Induction of CRMP-2 by GDNF and analysis of the CRMP-2 promoter region | Q40543376 | ||
| Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons | Q40592671 | ||
| Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment | Q41473213 | ||
| LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model | Q41539639 | ||
| Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice. | Q41745623 | ||
| Trehalose Improves Cognition in the Transgenic Tg2576 Mouse Model of Alzheimer's Disease. | Q41852404 | ||
| Regulation of mitochondrial morphology by USP30, a deubiquitinating enzyme present in the mitochondrial outer membrane | Q42070422 | ||
| Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease | Q42116615 | ||
| GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. | Q42141352 | ||
| In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease | Q42484469 | ||
| Collapsin response mediator proteins (CRMPs) are a new class of microtubule-associated protein (MAP) that selectively interacts with assembled microtubules via a taxol-sensitive binding interaction | Q42575131 | ||
| Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease | Q42603612 | ||
| CCAAT/Enhancer binding protein β silencing mitigates glial activation and neurodegeneration in a rat model of Parkinson's disease | Q42670542 | ||
| Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer's pathology. | Q42683481 | ||
| Beclin1 and HMGB1 ameliorate the α-synuclein-mediated autophagy inhibition in PC12 cells | Q43025000 | ||
| Transgenic expression of human wild-type amyloid precursor protein decreases neurogenesis in the adult hippocampus | Q43284371 | ||
| Activation of Trk neurotrophin receptor signaling by pituitary adenylate cyclase-activating polypeptides | Q43850091 | ||
| The antioxidant Trolox helps recovery from the familial Parkinson's disease-specific mitochondrial deficits caused by PINK1- and DJ-1-deficiency in dopaminergic neuronal cells | Q43965888 | ||
| Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease. | Q44037308 | ||
| Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia | Q44276700 | ||
| Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease | Q44317057 | ||
| Neurodegenerative diseases and oxidative stress | Q44805871 | ||
| Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease | Q44909742 | ||
| Insulin-like growth factor-I is necessary for neural stem cell proliferation and demonstrates distinct actions of epidermal growth factor and fibroblast growth factor-2. | Q45879665 | ||
| Dimethyl fumarate mediates Nrf2-dependent mitochondrial biogenesis in mice and humans. | Q46020398 | ||
| SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling | Q46218230 | ||
| Oxidative stress and cellular pathologies in Parkinson's disease. | Q46252606 | ||
| Oxidative stress and the amyloid beta peptide in Alzheimer's disease | Q46272723 | ||
| Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise | Q46297382 | ||
| CRMP2 hyperphosphorylation is characteristic of Alzheimer's disease and not a feature common to other neurodegenerative diseases | Q46491847 | ||
| Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons | Q46697248 | ||
| Trehalose rescues Alzheimer's disease phenotypes in APP/PS1 transgenic mice | Q46935089 | ||
| Autophagy impairment in Parkinson's disease. | Q47301116 | ||
| An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. | Q47393680 | ||
| Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression | Q47597706 | ||
| Allopregnanolone and its analog BR 297 rescue neuronal cells from oxidative stress-induced death through bioenergetic improvement. | Q47851415 | ||
| Aqua-soluble DDQ reduces the levels of Drp1 and Aβ and inhibits abnormal interactions between Aβ and Drp1 and protects Alzheimer's disease neurons from Aβ- and Drp1-induced mitochondrial and synaptic toxicities | Q47882705 | ||
| A novel class of thiosemicarbazones show multi-functional activity for the treatment of Alzheimer's disease | Q47905869 | ||
| Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease | Q47909812 | ||
| Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease | Q48003270 | ||
| Phosphodiesterase7 Inhibition Activates Adult Neurogenesis in Hippocampus and Subventricular Zone In Vitro and In Vivo | Q48105573 | ||
| TFEB links autophagy to lysosomal biogenesis | Q29614835 | ||
| Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains | Q29616293 | ||
| Alzheimer's disease | Q30251865 | ||
| Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. | Q30357397 | ||
| Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial | Q30407589 | ||
| A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease | Q30433751 | ||
| Robust pacemaking in substantia nigra dopaminergic neurons | Q30492001 | ||
| Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease | Q30540027 | ||
| Progranulin protects against amyloid β deposition and toxicity in Alzheimer's disease mouse models. | Q30592224 | ||
| Substance P inhibits progesterone conversion to neuroactive metabolites in spinal sensory circuit: a potential component of nociception | Q33216935 | ||
| Modulation of neurosteroid production in human neuroblastoma cells by Alzheimer's disease key proteins | Q33242184 | ||
| Neurotrophic effects of tianeptine on hippocampal neurons: a proteomic approach | Q33517724 | ||
| Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. | Q33537213 | ||
| Activity and injury-dependent expression of inducible transcription factors, growth factors and apoptosis-related genes within the central nervous system | Q33542011 | ||
| Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model | Q33608424 | ||
| Interferon-gamma produced by microglia and the neuropeptide PACAP have opposite effects on the viability of neural progenitor cells | Q33608621 | ||
| Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases | Q33613123 | ||
| Parkinson Disease: An Evolutionary Perspective | Q33619405 | ||
| Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature | Q33707896 | ||
| Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations | Q33836384 | ||
| Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models | Q33865366 | ||
| Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases | Q34179881 | ||
| Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice | Q34376186 | ||
| Acidic nanoparticles are trafficked to lysosomes and restore an acidic lysosomal pH and degradative function to compromised ARPE-19 cells | Q34524822 | ||
| Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. | Q34646166 | ||
| USP8 regulates mitophagy by removing K6-linked ubiquitin conjugates from parkin | Q34815182 | ||
| Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients | Q35183919 | ||
| The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys | Q35196195 | ||
| Mitochondrial Dysfunction and α-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First? | Q35412397 | ||
| Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration | Q35542169 | ||
| The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. | Q35558459 | ||
| Exogenous α-synuclein induces toll-like receptor 4 dependent inflammatory responses in astrocytes | Q35766124 | ||
| Deubiquitinating enzymes regulate PARK2-mediated mitophagy | Q35853250 | ||
| Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease | Q35865526 | ||
| PGC-1alpha: turbocharging mitochondria | Q35904070 | ||
| ??? | Q64767196 | ||
| The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. | Q35908404 | ||
| PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis | Q36016406 | ||
| An update of safety of clinically used atypical antipsychotics | Q36062184 | ||
| Mitochondrial Quality Control via the PGC1α-TFEB Signaling Pathway Is Compromised by Parkin Q311X Mutation But Independently Restored by Rapamycin | Q36064409 | ||
| Autophagy: dual roles in life and death? | Q36146947 | ||
| Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo. | Q36415259 | ||
| Direct Transcriptional Effects of Apolipoprotein E | Q36480230 | ||
| Mutant α-synuclein and aging reduce neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. | Q36641684 | ||
| Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease | Q36653826 | ||
| TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity | Q36835587 | ||
| In vivo silencing of alpha-synuclein using naked siRNA | Q37033987 | ||
| Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models | Q37048487 | ||
| Collapsin Response Mediator Protein-2 (CRMP2) is a Plausible Etiological Factor and Potential Therapeutic Target in Alzheimer's Disease: Comparison and Contrast with Microtubule-Associated Protein Tau | Q37089388 | ||
| A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism | Q37096051 | ||
| Role of α-synuclein in adult neurogenesis and neuronal maturation in the dentate gyrus | Q37128532 | ||
| Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein | Q37213687 | ||
| Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy | Q37213903 | ||
| Quercetin induces mitochondrial biogenesis in experimental traumatic brain injury via the PGC-1α signaling pathway | Q37228027 | ||
| Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta. | Q37257169 | ||
| Complement component 3 (C3) expression in the hippocampus after excitotoxic injury: role of C/EBPβ. | Q37356880 | ||
| Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease | Q37539279 | ||
| PINK1, Parkin, and Mitochondrial Quality Control: What can we Learn about Parkinson's Disease Pathobiology? | Q37635610 | ||
| Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes | Q37653023 | ||
| Neuroinflammation in the living brain of Parkinson's disease | Q37677181 | ||
| Nix restores mitophagy and mitochondrial function to protect against PINK1/Parkin-related Parkinson's disease | Q37692348 | ||
| The Revitalized Tau Hypothesis on Alzheimer's Disease | Q37777458 | ||
| Neurotrophic factor therapy for Parkinson’s disease | Q37796025 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 719 | |
| P577 | publication date | 2019-01-01 | |
| 2019-02-08 | |||
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Novel Approaches for the Treatment of Alzheimer's and Parkinson's Disease | |
| Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease | |||
| P478 | volume | 20 |
| Q90162519 | An Update of Palmitoylethanolamide and Luteolin Effects in Preclinical and Clinical Studies of Neuroinflammatory Events |
| Q91635268 | Brain-Region Specific Metabolic Abnormalities in Parkinson's Disease and Levodopa-Induced Dyskinesia |
| Q64057778 | Contributions of Mass Spectrometry to the Identification of Low Molecular Weight Molecules Able to Reduce the Toxicity of Amyloid-β Peptide to Cell Cultures and Transgenic Mouse Models of Alzheimer's Disease |
| Q100316248 | N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo |
| Q64112436 | Neuroprotective Effects of Thymol, a Dietary Monoterpene Against Dopaminergic Neurodegeneration in Rotenone-Induced Rat Model of Parkinson's Disease |
| Q92636628 | Polyphenols from Food and Natural Products: Neuroprotection and Safety |
| Q91801192 | Potential Benefits of Nobiletin, A Citrus Flavonoid, against Alzheimer's Disease and Parkinson's Disease |
| Q91637190 | Prion-Like Mechanisms in Parkinson's Disease |
| Q92755742 | Putative Roles of Plant-Derived Tannins in Neurodegenerative and Neuropsychiatry Disorders: An Updated Review |
| Q94502456 | Resveratrol Derivatives as Potential Treatments for Alzheimer's and Parkinson's Disease |
| Q89745734 | The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases |
Search more.